{"filing":{"accession_number":"0001493152-26-027752","cik":"0001971532","ticker":"TELO","company_name":"Telomir Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226027752/form8-k.htm"},"events":[{"id":6311,"run_id":5531,"accession_number":"0001493152-26-027752","anchor_item_number":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The filing discloses the appointment of Andriy Mushak as fractional Chief Financial Officer effective June 6, 2026, following the departure of Alan Weichselbaum. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a new CFO with detailed background information and compensation terms ($6,000/month). This is material as CFO changes affect investor assessment of financial reporting and governance.","company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":5313,"accession_number":"0001493152-26-027752","item_number":null,"item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Andriy Mushak as fractional Chief Financial Officer effective June 6, 2026, following the departure of Alan Weichselbaum. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a new CFO with detailed background information and compensation terms ($6,000/month). This is material as CFO changes affect investor assessment of financial reporting and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T21:02:06.107462+00:00","company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","filing_date":"2026-06-08"}]}